Literature DB >> 27939925

A candidate regulatory variant at the TREM gene cluster associates with decreased Alzheimer's disease risk and increased TREML1 and TREM2 brain gene expression.

Minerva M Carrasquillo1, Mariet Allen1, Jeremy D Burgess1, Xue Wang2, Samantha L Strickland1, Shivani Aryal1, Joanna Siuda1, Michaela L Kachadoorian1, Christopher Medway3, Curtis S Younkin1, Asha Nair4, Chen Wang4, Pritha Chanana4, Daniel Serie2, Thuy Nguyen1, Sarah Lincoln1, Kimberly G Malphrus1, Kevin Morgan5, Todd E Golde6, Nathan D Price7, Charles C White8, Philip L De Jager9, David A Bennett10, Yan W Asmann2, Julia E Crook2, Ronald C Petersen11, Neill R Graff-Radford12, Dennis W Dickson1, Steven G Younkin1, Nilüfer Ertekin-Taner13.   

Abstract

INTRODUCTION: We hypothesized that common Alzheimer's disease (AD)-associated variants within the triggering receptor expressed on myeloid (TREM) gene cluster influence disease through gene expression.
METHODS: Expression microarrays on temporal cortex and cerebellum from ∼400 neuropathologically diagnosed subjects and two independent RNAseq replication cohorts were used for expression quantitative trait locus analysis.
RESULTS: A variant within a DNase hypersensitive site 5' of TREM2, rs9357347-C, associates with reduced AD risk and increased TREML1 and TREM2 levels (uncorrected P = 6.3 × 10-3 and 4.6 × 10-2, respectively). Meta-analysis on expression quantitative trait locus results from three independent data sets (n = 1006) confirmed these associations (uncorrected P = 3.4 × 10-2 and 3.5 × 10-3, Bonferroni-corrected P = 6.7 × 10-2 and 7.1 × 10-3, respectively). DISCUSSION: Our findings point to rs9357347 as a functional regulatory variant that contributes to a protective effect observed at the TREM locus in the International Genomics of Alzheimer's Project genome-wide association study meta-analysis and suggest concomitant increase in TREML1 and TREM2 brain levels as a potential mechanism for protection from AD.
Copyright © 2016 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Regulatory variant; TREM2; TREML1; eQTL

Mesh:

Substances:

Year:  2016        PMID: 27939925      PMCID: PMC5462884          DOI: 10.1016/j.jalz.2016.10.005

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  36 in total

1.  TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis.

Authors:  Gernot Kleinberger; Yoshinori Yamanishi; Marc Suárez-Calvet; Eva Czirr; Ebba Lohmann; Elise Cuyvers; Hanne Struyfs; Nadine Pettkus; Andrea Wenninger-Weinzierl; Fargol Mazaheri; Sabina Tahirovic; Alberto Lleó; Daniel Alcolea; Juan Fortea; Michael Willem; Sven Lammich; José L Molinuevo; Raquel Sánchez-Valle; Anna Antonell; Alfredo Ramirez; Michael T Heneka; Kristel Sleegers; Julie van der Zee; Jean-Jacques Martin; Sebastiaan Engelborghs; Asli Demirtas-Tatlidede; Henrik Zetterberg; Christine Van Broeckhoven; Hakan Gurvit; Tony Wyss-Coray; John Hardy; Marco Colonna; Christian Haass
Journal:  Sci Transl Med       Date:  2014-07-02       Impact factor: 17.956

2.  TREM2 and Risk of Alzheimer's Disease--Friend or Foe?

Authors:  Rudolph E Tanzi
Journal:  N Engl J Med       Date:  2015-06-25       Impact factor: 91.245

3.  Trem-like transcript 2 is expressed on cells of the myeloid/granuloid and B lymphoid lineage and is up-regulated in response to inflammation.

Authors:  R Glenn King; Brantley R Herrin; Louis B Justement
Journal:  J Immunol       Date:  2006-05-15       Impact factor: 5.422

4.  A TREM1 variant alters the accumulation of Alzheimer-related amyloid pathology.

Authors:  Joseph M Replogle; Gail Chan; Charles C White; Towfique Raj; Phoebe A Winn; Denis A Evans; Reisa A Sperling; Lori B Chibnik; Elizabeth M Bradshaw; Julie A Schneider; David A Bennett; Philip L De Jager
Journal:  Ann Neurol       Date:  2015-03       Impact factor: 10.422

5.  Variant of TREM2 associated with the risk of Alzheimer's disease.

Authors:  Thorlakur Jonsson; Hreinn Stefansson; Stacy Steinberg; Ingileif Jonsdottir; Palmi V Jonsson; Jon Snaedal; Sigurbjorn Bjornsson; Johanna Huttenlocher; Allan I Levey; James J Lah; Dan Rujescu; Harald Hampel; Ina Giegling; Ole A Andreassen; Knut Engedal; Ingun Ulstein; Srdjan Djurovic; Carla Ibrahim-Verbaas; Albert Hofman; M Arfan Ikram; Cornelia M van Duijn; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

6.  The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease.

Authors:  Christina M Lill; Aina Rengmark; Lasse Pihlstrøm; Isabella Fogh; Aleksey Shatunov; Patrick M Sleiman; Li-San Wang; Tian Liu; Christina F Lassen; Esther Meissner; Panos Alexopoulos; Andrea Calvo; Adriano Chio; Nil Dizdar; Frank Faltraco; Lars Forsgren; Julia Kirchheiner; Alexander Kurz; Jan P Larsen; Maria Liebsch; Jan Linder; Karen E Morrison; Hans Nissbrandt; Markus Otto; Jens Pahnke; Amanda Partch; Gabriella Restagno; Dan Rujescu; Cathrin Schnack; Christopher E Shaw; Pamela J Shaw; Hayrettin Tumani; Ole-Bjørn Tysnes; Otto Valladares; Vincenzo Silani; Leonard H van den Berg; Wouter van Rheenen; Jan H Veldink; Ulman Lindenberger; Elisabeth Steinhagen-Thiessen; Stefan Teipel; Robert Perneczky; Hakon Hakonarson; Harald Hampel; Christine A F von Arnim; Jørgen H Olsen; Vivianna M Van Deerlin; Ammar Al-Chalabi; Mathias Toft; Beate Ritz; Lars Bertram
Journal:  Alzheimers Dement       Date:  2015-04-30       Impact factor: 21.566

7.  Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants.

Authors:  Fanggeng Zou; High Seng Chai; Curtis S Younkin; Mariet Allen; Julia Crook; V Shane Pankratz; Minerva M Carrasquillo; Christopher N Rowley; Asha A Nair; Sumit Middha; Sooraj Maharjan; Thuy Nguyen; Li Ma; Kimberly G Malphrus; Ryan Palusak; Sarah Lincoln; Gina Bisceglio; Constantin Georgescu; Naomi Kouri; Christopher P Kolbert; Jin Jen; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg; Ronald C Petersen; Neill R Graff-Radford; Dennis W Dickson; Steven G Younkin; Nilüfer Ertekin-Taner
Journal:  PLoS Genet       Date:  2012-06-07       Impact factor: 5.917

8.  TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model.

Authors:  Yaming Wang; Marina Cella; Kaitlin Mallinson; Jason D Ulrich; Katherine L Young; Michelle L Robinette; Susan Gilfillan; Gokul M Krishnan; Shwetha Sudhakar; Bernd H Zinselmeyer; David M Holtzman; John R Cirrito; Marco Colonna
Journal:  Cell       Date:  2015-02-26       Impact factor: 41.582

9.  TREM2 variants in Alzheimer's disease.

Authors:  Rita Guerreiro; Aleksandra Wojtas; Jose Bras; Minerva Carrasquillo; Ekaterina Rogaeva; Elisa Majounie; Carlos Cruchaga; Celeste Sassi; John S K Kauwe; Steven Younkin; Lilinaz Hazrati; John Collinge; Jennifer Pocock; Tammaryn Lashley; Julie Williams; Jean-Charles Lambert; Philippe Amouyel; Alison Goate; Rosa Rademakers; Kevin Morgan; John Powell; Peter St George-Hyslop; Andrew Singleton; John Hardy
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

10.  Missense variant in TREML2 protects against Alzheimer's disease.

Authors:  Bruno A Benitez; Sheng Chih Jin; Rita Guerreiro; Rob Graham; Jenny Lord; Denise Harold; Rebecca Sims; Jean-Charles Lambert; J Raphael Gibbs; Jose Bras; Celeste Sassi; Oscar Harari; Sarah Bertelsen; Michelle K Lupton; John Powell; Celine Bellenguez; Kristelle Brown; Christopher Medway; Patrick C G Haddick; Marcel P van der Brug; Tushar Bhangale; Ward Ortmann; Tim Behrens; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Gerard D Schellenberg; Jonathan L Haines; Jim Turton; Anne Braae; Imelda Barber; Anne M Fagan; David M Holtzman; John C Morris; Julie Williams; John S K Kauwe; Philippe Amouyel; Kevin Morgan; Andy Singleton; John Hardy; Alison M Goate; Carlos Cruchaga
Journal:  Neurobiol Aging       Date:  2013-12-21       Impact factor: 4.673

View more
  23 in total

Review 1.  Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders.

Authors:  Todd E Golde
Journal:  Neuron       Date:  2019-03-20       Impact factor: 17.173

2.  Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer's Disease Models.

Authors:  C Y Daniel Lee; Anthony Daggett; Xiaofeng Gu; Lu-Lin Jiang; Peter Langfelder; Xiaoguang Li; Nan Wang; Yingjun Zhao; Chang Sin Park; Yonatan Cooper; Isabella Ferando; Istvan Mody; Giovanni Coppola; Huaxi Xu; X William Yang
Journal:  Neuron       Date:  2018-03-07       Impact factor: 17.173

3.  iDHS-FFLG: Identifying DNase I Hypersensitive Sites by Feature Fusion and Local-Global Feature Extraction Network.

Authors:  Lei-Shan Wang; Zhan-Li Sun
Journal:  Interdiscip Sci       Date:  2022-09-27       Impact factor: 3.492

Review 4.  Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer's disease: review, recommendation, implementation and application.

Authors:  Minghui Wang; Won-Min Song; Chen Ming; Qian Wang; Xianxiao Zhou; Peng Xu; Azra Krek; Yonejung Yoon; Lap Ho; Miranda E Orr; Guo-Cheng Yuan; Bin Zhang
Journal:  Mol Neurodegener       Date:  2022-03-02       Impact factor: 18.879

5.  Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology.

Authors:  Kwangsik Nho; Kelly Nudelman; Mariet Allen; Angela Hodges; Sungeun Kim; Shannon L Risacher; Liana G Apostolova; Kuang Lin; Katie Lunnon; Xue Wang; Jeremy D Burgess; Nilüfer Ertekin-Taner; Ronald C Petersen; Lisu Wang; Zhenhao Qi; Aiqing He; Isaac Neuhaus; Vishal Patel; Tatiana Foroud; Kelley M Faber; Simon Lovestone; Andrew Simmons; Michael W Weiner; Andrew J Saykin
Journal:  Alzheimers Dement       Date:  2020-08-05       Impact factor: 21.566

6.  Candidate-based screening via gene modulation in human neurons and astrocytes implicates FERMT2 in Aβ and TAU proteostasis.

Authors:  Sarah E Sullivan; Meichen Liao; Robert V Smith; Charles White; Valentina N Lagomarsino; Jishu Xu; Mariko Taga; David A Bennett; Philip L De Jager; Tracy L Young-Pearse
Journal:  Hum Mol Genet       Date:  2019-03-01       Impact factor: 6.150

7.  Myeloid cell-like transcript 2 is related to liver inflammation and the pathogenesis of hepatitis B via the involvement of CD8+T cell activation.

Authors:  Jun-Chi Xu; Fei Gao; Yi-An Liu; Xiao-Long Zhang; Hui Chen; Xiao-Yan Zhu; Hua-Feng Song; Feng Qian; Ming Li; Chen Yang; Chuan-Wu Zhu; Ping Xu
Journal:  Clin Exp Med       Date:  2018-10-25       Impact factor: 3.984

8.  Imbalance of Microglial TLR4/TREM2 in LPS-Treated APP/PS1 Transgenic Mice: A Potential Link Between Alzheimer's Disease and Systemic Inflammation.

Authors:  Jian Zhou; Weihua Yu; Man Zhang; Xin Tian; Yu Li; Yang Lü
Journal:  Neurochem Res       Date:  2019-02-12       Impact factor: 3.996

9.  Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal.

Authors:  Silvia S Kang; Aishe Kurti; Kelsey E Baker; Chia-Chen Liu; Marco Colonna; Jason D Ulrich; David M Holtzman; Guojun Bu; John D Fryer
Journal:  Hum Mol Genet       Date:  2018-01-15       Impact factor: 6.150

Review 10.  TREM2 in Neurodegenerative Diseases.

Authors:  Taylor R Jay; Victoria E von Saucken; Gary E Landreth
Journal:  Mol Neurodegener       Date:  2017-08-02       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.